WINNIPEG, MANITOBA (AMEX: MCU), a cardiovascular-focused biopharmaceutical company, today announced a restructuring plan that will see the...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE...
WINNIPEG, MANITOBA (AMEX: MCU), a cardiovascular-focused biopharmaceutical company, today announced that an analysis of the data from its pivotal...
WINNIPEG, MANITOBA (AMEX: MCU), a cardiovascular focused biopharmaceutical company, today announced its President and CEO, Albert D. Friesen, PhD...
WINNIPEG, MANITOBA (AMEX: MCU), a cardiovascular-focused biopharmaceutical company, today announced that the results of the Company's pivotal...
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________ SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934...
WINNIPEG, MANITOBA (AMEX: MCU), a cardiovascular focused biopharmaceutical company, today reported the results of operations for the three and six...
WINNIPEG, MANITOBA (AMEX: MCU), a cardiovascular focused biopharmaceutical company, today announced that the Company will report second quarter...
WINNIPEG, MANITOBA (AMEX: MCU), a cardiovascular drug discovery and development company, today announced that David Banks has joined its Board of...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.